RESEARCH GROUP

Lugli Group

Translational Immunology Lab
  • Enrico Lugli Group Leader, Translational Immunology Lab
    Head, Flow Cytometry Core
    View More

Contact Information

  • Address
    Building C, Humanitas University Campus, Pieve Emanuele (MI), Italy
  • Telephone
    +39 02 8224 5143
  • E-mail
    enrico.lugli@humanitasresearch.it

The group applies high-dimensional approaches – such as single cell RNA sequencing, 30-parameter flow cytometry, spatial profiling and computational biology – to dissect the complexity of the immune system at the level of single cells, with the final aim to exploit memory T cell responses in cancer immunotherapy approaches.

___

The challenge

Immune checkpoint inhibitors have definitively proven that the immune system can mediate cancer regression. However, not all patients respond to therapies. This is in part due to the complexity of immune responses: there are several different subsets of T cells infiltrating human cancers, each one with different characteristics and potency against tumor cells. The only way to improve current therapies and identify novel targets is to dissect such complexity. By combining single cell approaches and advanced computational methods, we are now able to map immune activity in patients’ samples and identify T cell populations that can mediate regression of established tumors.

Main research areas

Stem-like memory T cell differentiation in cancer immunotherapy

Following our original studies on the identification of T stem cell memory cells (Gattinoni, Lugli et al., Nat Med, 2011; Lugli, et al., J Clin Invest, 2013), we were the first to show that a subset with enhanced functionality and stem-like properties exists among PD-1+ exhausted T cells in human tumors (Brummelman et al., J Exp Med, 2018). More recently, by using omics technologies, we have redefined the model of memory T cell differentiation in humans by reporting the existence of two subsets of stem-like T cell progenitors with parallel differentiation programs and distinct fate commitments, functional vs. dysfunctional (Galletti et al., Nature Immunol, 2020). Once acquired, these traits of dysfunction cannot be reverted: they are “hard-wired” to the differentiation program. Our major question is now to define the niche of stem-like subsets in tumor tissues to understand how stromal, tumoral and immune cells regulate their differentiation and function.

Immunosuppression in the tumor microenvironment

The landscape of immune cells infiltrating tumors is highly complex. We recently identified unprecedented cellular players mediating immunosuppression and driving disease progression in several human cancers’ microenvironment. We found that the differentiation and function of a subset of highly suppressive effector regulatory T (Treg) cells is governed by the expression of two key transcription factors: interferon regulatory factor 4, IRF4 (Alvisi et al., J Clin Invest, 2020), and mesenchyme homeobox-1, MEOX-1 (MEOX-1; Alvisi et al., J Hepatol, 2022). A major question is how Tregs sustain chronic activation and resist exhaustion and senescence. We will address this by using novel sequencing and proteomic technologies applied to primary patients’ samples.

    Selected Publications

  • Lugli selected publications

    Alvisi G, Termanini A, Soldani C, Portale F, Carriero R, Pilipow K, Costa G, Polidoro M, Franceschini B, Malenica I, Puccio S, Lise V, Galletti G, Zanon V, Colombo FS, ...

Group Members